As a global leader in genomics, we continually strive to offer solutions that are not only innovative, but also accessible and always reliable. Illumina partnerships help advance genomics in numerous ways, from expanding access to next-generation sequencing (NGS) to pioneering new applications and technologies, providing funding for innovative startups, and more.
Some of our existing partnerships include:
Illumina and Roche partner to broaden the adoption of distributable next-generation sequencing-based testing in oncology.Read Press Release
Illumina forms multiple partnerships to develop precision oncology solutions.Read Press Release
Illumina and Loxo Oncology partner to develop next-generation sequencing-based pan-cancer companion diagnostics.Read Press Release
Discover more Illumina partnerships and collaborations designed to advance access to groundbreaking genomics solutions.
The partnership aims to accelerate NGS adoption for clinical infectious disease testing.
The partnership focuses on commercializing oncology In Vitro Diagnostc (IVD) kits to support patient management and may expand to other clinical fields in the future.
The partnership involves integrating Illumina DRAGEN Pipelines and technology with the Broad’s Genome Analysis Toolkit (GATK) to develop new methods.
We strive to offer the best possible technologies and solutions to our customers. By integrating our technology with other best-in-class solutions, we aim to improve workflows, support groundbreaking research, and continue advancing genomics.Learn More
With mentorship, financial support, and access to sequencers and reagents, the Illumina Accelerator is helping genomics startups launch so we can unlock the power of the genome—together.Illumina Accelerator Startup Funding